Table 6. Gene targets and functional analysis of the three top predictions of the transportable miRNAs in cow’s milk, EBV, and rLCV.
| Dietary miRNAs | Human homologs with identical sequences | Number of targets | Related functional processes | |||
|---|---|---|---|---|---|---|
| Experimentally validated | Predicated | Enriched pathway examples | Enriched GO term examples | |||
| Cow | bta-miR-487b | hsa-miR-487b-3p | 46 | 468 | Axon guidance (4.2E-2); Regulation of actin cytoskeleton (4.2E-2); Butanoate metabolism (5.2E-2); MAPK signaling pathway (3.4E-2). | Cell migration (8.0E-3); Positive regulation of locomotion (9.8E-3); Localization of cell (1.2E-2); Protein kinase activity (1.8E-2). |
| bta-miR-181b | hsa-miR-181b-5p | 1077 | 2084 | Glioma (5.8E-3); Melanoma (8.1E-3); p53 Signaling Pathway (2.6E-2); Prostate cancer (1.0E-5). | Organelle lumen (7.3E-9); Nuclear envelope (9.5E-5); Intracellular non-membrane-bounded Organelle (1.4E-4). | |
| bta-miR-421 | hsa-miR-421 | 793 | 808 | Huntington's disease (3.5E-2); Hypoxia and p53 in the Cardiovascular system (4.6E-2); Apoptotic Signaling in Response to DNA Damage (3.6E-2). | Endomembrane system (4.6E-5); Nuclear lumen (7.8E-5); Establishment of protein localization (1.6E-4); Intracellular transport (2.8E-4). | |
| EBV | ebv-mir-BART13-3p | - | - | 208 | Long-term potentiation (3.3E-2); Neurotrophin signaling pathway (3.9E-2); ErbB signaling pathway (6.1E-2); Melanogenesis (8.3E-2). | Phosphate metabolic process (1.2E-4); Wnt receptor signaling pathway (4.7E-2); hosphorylation (1.3E-3); Enzyme linked receptor protein signaling pathway (2.6E-3). |
| ebv-mir-BART8-3p | - | - | 549 | Aldosterone-regulated sodium reabsorption (6.5E-3); Growth factors Survival factors Mitogens (2.3E-2); Prostate cancer (4.5E-2); Renal cell carcinoma (5.3E-2). | Nuclear lumen (5.6E-5); Transcriptional repressor complex (6.2E-5); Synapse (8.8E-5); Nucleoplasm (8.8E-5). | |
| ebv-mir-BART9-3p | - | - | 568 | Adherens junction (1.4E-2); Endocytosis (2.0E-2); Signaling Pathway from G-Protein Families (5.4E-2); Cell cycle (5.9E-2). | Membrane raft (1.5E-4); Regulation of transcription (1.8E-4); Regulation of transcription from RNA polymerase II promoter (3.4E-4); Positive regulation of macromolecule metabolic process (3.8E-4). | |
| rLCV | rLCV-mir-rl1-16-3p | - | - | 466 | Fc gamma R-mediated phagocytosis (5.8E-4); Ubiquitin mediated proteolysis (6.0E-4); Endocytosis (6.6E-4); Melanoma (1.9E-3). | Regulation of endocytosis (1.0E-4); protein modification by small protein Conjugation or removal (1.4E-4); Extrinsic to membrane (5.7E-4). |
| rLCV-mir-rl1-16-5p | - | - | 403 | Regulation of actin cytoskeleton (5.6E-4); Ca++/ Calmodulin-dependent Protein Kinase Activation (7.9E-3); Vascular smooth muscle contraction (9.3E-3); Focal adhesion (9.9E-3). | Positive regulation of cell migration (1.2E-4); Cytoskeleton (2.0E-4); Positive regulation of locomotion (2.6E-4). | |
| rLCV-mir-rl1-7-3p | - | - | 228 | Axon guidance (6.9E-3); Adherens junction (3.5E-2); Metabolism of Anandamide (5.7E-2). | Intrinsic to membrane (1.8E-4); Alkali metal ion binding (9.0E-4); Plasma membrane part (1.6E-3); Metal ion transport (1.7E-3). | |
The experimentally validated targets are collected from CLASH, MirTarBase and DIANA-TarBase; the complete list of the enriched pathways and GOs are listed in Table D in S1 File.